Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan

Asghar, Kashif; Loya, Asif; Rana, Iftikhar Ali; Bakar, Muhammad Abu; Farooq, Asim V.; Tahseen, Muhammad; Ishaq, Muhammad; Rashid, Muhammad Usman

doi:10.31557/apjcp.2019.20.11.3521

Cited by 5 publications

(4 citation statements)

References 29 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cancer types such as breast and colorectal, IDO1 co-expressed with cyclooxygenase-2 (COX2) is a weak independent predictor for overall survival [ 64 ]. Also, in triple-negative breast cancer, the expression of IDO1 has an association with forkhead box P3 (FoxP3) positive cells [ 65 ].…”

Section: Ido Expresses In Various Cancer Typesmentioning

confidence: 99%

Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment

et al. 2023

View full text Add to dashboard Cite

Indoleamine-2,3 dioxygenase is a rate-limiting enzyme in the tryptophan catabolism in kynurenine pathways that has an immunosuppressive effect and supports cancer cells to evade the immune system in different cancer types. Diverse cytokines and pathways upregulate the production of indoleamine-2,3 dioxygenase enzymes in the tumor microenvironment and cause more production and activity of this enzyme. Ultimately, this situation results in anti-tumor immune suppression which is in favor of tumor growth. Several inhibitors such as 1-methyl-tryptophan have been introduced for indoleamine-2,3 dioxygenase enzyme and some of them are widely utilized in pre-clinical and clinical trials. Importantly at the molecular level, indoleamine-2,3 dioxygenase is positioned in a series of intricate signaling and molecular networks. Here, the main objective is to provide a focused view of indoleamine-2,3 dioxygenase enhancer pathways and propose further studies to cover the gap in available information on the function of indoleamine-2,3 dioxygenase enzyme in the tumor microenvironment.

show abstract

Section: Ido Expresses In Various Cancer Typesmentioning

confidence: 99%

Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It plays a physiological and pathological role by inducing arachidonic acid to transform into prostaglandin. Multiple malignant tumors may be promoted by COX-2 over-expression, which is brought on by the activation of growth factors, inflammatory cytokines, endotoxins, or oncogenes [9]. After down-regulation of COX-2 expression, it can promote cell apoptosis, inhibit angiogenesis, enhance cellular immunity and act as an anti-tumor agent [10more evidence is needed for clinical application.…”

Section: Figure1 Chemical Structure Of Oridoninmentioning

confidence: 99%

Oridonin inhibits breast cancer cell proliferation and migrationthrough suppressing COX-2 expression

Yao

2023

View full text Add to dashboard Cite

Oridonin, a biologically active substance isolated from the plant Rabdosia rubescens, is recently reported to have aninhibitory effect on breast cancer. However, its mechanism is still unclear. According to previous findings, increasedCOX-2 expression has been associated with a higher incidence of breast cancer. Therefore, this study aims to explorewhether oridonin inhibits cell proliferation and migration by suppressing the expression of COX-2 in human breastcancer cells MDA-MB-231 in vitro and in vivo conditions. In this study, human breast cancer cells MDA-MB-231will be treated with increasing concentrations and for various durations with oridonin to investigate whether oridonininhibits cell migration, decrease proliferation, and reduce tumors in mice through suppressing the expression of COX2. A positive control is a taxol. A negative control is medium. Cell migration will be tested by Transwell assay. Theproliferation will be detected by MTT assay. The western-blotting assay will be used for COX-2. In nude mice, the invivo anti-tumor efficacy of oridonin will be examined. The study’s result will provide insight into the effect of oridoninon the proliferation and migration of human breast cancer cells MDA-MB-231. It will also provide reference for themechanism of how oridonin inhibits breast cancer and lay the foundation for future studies on the molecular basis oforidonin’s pharmacological activity in the future.

show abstract

“…The team also proposed that inhibiting both of these pathways might act as a novel therapeutic strategy in breast cancer treatment[ 34 ]. Another study published by Asghar et al [ 35 ] reported that high IDO expression was correlated with high cyclooxygenase-2 expression in breast cancer patients. It was suggested that the simultaneous targeting of cyclooxygenase-2 and IDO may have potential for treatment of breast cancer[ 35 ].…”

Section: Therapeutic and Prognostic Significance Of Idomentioning

confidence: 99%

“…Another study published by Asghar et al [ 35 ] reported that high IDO expression was correlated with high cyclooxygenase-2 expression in breast cancer patients. It was suggested that the simultaneous targeting of cyclooxygenase-2 and IDO may have potential for treatment of breast cancer[ 35 ]. Carvajal-Hausdorf et al [ 36 ] observed that the IDO protein was expressed in hormone receptor-positive breast cancer.…”

Section: Therapeutic and Prognostic Significance Of Idomentioning

confidence: 99%

Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase

Asghar¹,

Farooq²,

Zulfiqar³

et al. 2021

WJCO

Self Cite

View full text Add to dashboard Cite

Therapeutic manipulation of the immune system in cancer has been an extensive area of research in the field of oncoimmunology. Immunosuppression regulates antitumour immune responses. An immunosuppressive enzyme, indoleamine 2,3-dioxygenase (IDO) mediates tumour immune escape in various malignancies including breast cancer. IDO upregulation in breast cancer cells may lead to the recruitment of regulatory T (T-regs) cells into the tumour microenvironment, thus inhibiting local immune responses and promoting metastasis. Immunosuppression induced by myeloid derived suppressor cells activated in an IDO-dependent manner may enhance the possibility of immune evasion in breast cancer. IDO overexpression has independent prognostic significance in a subtype of breast cancer of emerging interest, basal-like breast carcinoma. IDO inhibitors as adjuvant therapeutic agents may have clinical implications in breast cancer. This review proposes future prospects of IDO not only as a therapeutic target but also as a valuable prognostic marker for breast cancer.

show abstract

Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan

Cited by 5 publications

References 29 publications

Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment

Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment

Oridonin inhibits breast cancer cell proliferation and migrationthrough suppressing COX-2 expression

Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase

Contact Info

Product

Resources

About